Mallinckrodt plc (MNK) shares are rising over 14.65% in pre-market today, after the company and Novoteris announced that they have received clearance from Health Canada to start pilot trial of high-dose Inhaled Nitric Oxide therapy for COVID-19 infection and associated lung complications.
from RTT - Before the Bell https://ift.tt/2wSOUY8
via IFTTT
No comments:
Post a Comment